Is ASRT or BCRX more undervalued in 2026?

CirclFi compares Assertio Holdings, Inc. (ASRT) and BioCryst Pharmaceuticals, Inc. (BCRX) using 13 institutional-grade valuation models. ASRT has a Quality of Company score of 5.4/10 while BCRX scores 6.9/10.

Which is a better buy — ASRT or BCRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ASRT and BCRX valuations compare?

ASRT at $23.44 and BCRX at $9.10 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ASRT vs BCRX Valuation Comparison 2026 — Intrinsic Value Analysis

ASRT

Drug Manufacturers - Specialty & Generic

Assertio Holdings, Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$23.44

Last close

Models

10/13

Active

BCRX

Drug Manufacturers - Specialty & Generic

BioCryst Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$9.10

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	ASRT Fair Value	ASRT Upside	BCRX Fair Value	BCRX Upside
Bayesian DCF	Intrinsic	$50.65	+116.1%	$14.22	+66.7%
Earnings Power Value	Intrinsic	—	—	$2.33	-74.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$76.95	+228.3%	$2.10	-74.9%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ASRT vs BCRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ASRT vs BCRX — Which Stock Is More Undervalued?

BCRX scores higher with a 6.9/10 quality rating vs ASRT's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Assertio Holdings, Inc. (ASRT) and BioCryst Pharmaceuticals, Inc. (BCRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ASRT currently trades at $23.44 with a QOC of 5.4/10, while BCRX trades at $9.10 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).